GREHTA G

Idioma: Inglés [English version]
Referencias bibliográficas: 12
Paginas: 5-7
Archivo PDF: 264.30 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Jay V. Richard bright-physician extraordinaire. Arch Pathol Lab Med. 2024; 124: 1262-1263. Available in: https://doi.org/10.5858/2000-124-1262-RBPE

2. O'Rourke MF. Frederick Akbar Mahomed. Hypertension. 1992; 19: 212-217. https://doi.org/10.1161/01.HYP.19.2.212

3. National Heart, Lung, and Blood Institute. NHLBI Working Group: cardiorenal connections in heart failure and cardiovascular disease, 2004. 2004. [Accessed February 18, 2025] Available in: https://www.nhlbi.nih.gov/events/2004/cardio-renal-connections-heartfailure-and-cardiovascular-disease

4. Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019; 139 (16): e840-e878. doi: 10.1161/CIR.0000000000000664.

5. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023; 148 (20): 1606-1635. doi: 10.1161/CIR.0000000000001184.

6. Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023; 148 (20): 1636-1664. doi: 10.1161/CIR.0000000000001186.

7. INEGI Estadísticas de Defunciones Registradas 2023 (Consultado el 18 de diciembre 2024). Disponible en: https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2024/EDR/EDR2023_ene-dic.pdf

8. Meaney E, Pérez-Robles E, Ortiz-Flores M, Perez-Ishiwara G, Meaney A, Munguía L et al. Overweight, obesity, and age are the main determinants of cardiovascular risk aggregation in the current mexican population: the FRIMEX III study. J Clin Med. 2024; 13 (8): 2248. doi: 10.3390/jcm13082248.

9. Manoria PC, Chopra HK, Parashar SK, Dutta AL, Pinto B, Mullasari A et al. The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies. Indian Heart J. 2013; 65 (6): 683-690. doi: 10.1016/j.ihj.2013.10.015.

10. Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. 2024; 65 (1): 100485. doi: 10.1016/j.jlr.2023.100485.

11. Zhang F, Chen Y, Heiman M, Dimarchi R. Leptin: structure, function and biology. Vitam Horm. 2005; 71: 345-372.

12. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021; 19 (1): 55-71. doi: 10.1038/s41579-020-0433-9.